Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Dauntless who wrote (3804)	5/2/1998 2:17:00 PM
From: Claud B	Read Replies (4) \| Respond to of 7041

Dauntless, It's been my experience that the FDA frowns on companies releasing trial data via the press or other media prior to NDA filings. ClaudB

To: Dauntless who wrote (3804)	5/2/1998 11:20:00 PM
From: Hank	Respond to of 7041

That is a company by company preference. Yes, Pfizer has traditionally withheld data from publication prior to a drug release in order to prevent a competitor from gaining an advantage. However, in ZONA's case, we are now talking about a drug which has been available for quite some time as an antihypertensive. What's the secret? I would think they would want to be as public as possible in order to dispel the allegations that it is a farse. The fact that they are acting to the contrary is BS and unacceptable.